首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1967751

過敏診斷和治療市場－全球產業規模、佔有率、趨勢、機會和預測：按類型、按過敏原類型、按檢測類型、按地區和競爭對手分類，2021-2031年

Allergy Diagnostics and Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Allergen Type, By Test Type, By Region & Competition, 2021-2031F

出版日期: 2026年01月19日 | 出版商:

TechSci Research | 英文 186 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球過敏診斷和治療市場預計將從 2025 年的 363.3 億美元成長到 2031 年的 576.2 億美元，複合年成長率為 7.99%。

此領域涵蓋用於識別和管理特定過敏原引起的超敏反應的醫療設備、檢測套組和藥物干預措施。市場成長的主要促進因素是全球過敏性疾病（例如過敏性鼻炎和食物過敏）盛行率的不斷上升，這些疾病需要獨特的臨床管理策略。此外，都市化加快和污染加劇導致人們更多地暴露於環境因素，這成為需要醫療保健的患者群體不斷擴大的主要驅動力。

市場概覽
預測期	2027-2031
市場規模：2025年	363.3億美元
市場規模：2031年	576.2億美元
複合年成長率：2026-2031年	7.99%
成長最快的細分市場	診斷
最大的市場	北美洲

儘管有這些積極跡象，但某些免疫療法方案和先進診斷試劑盒的高成本構成了市場准入的重大障礙，限制了對成本敏感的開發中國家患者的就醫機會。不完善的報銷機制往往會加劇這種經濟障礙，減緩創新治療方法的推廣。氣喘與過敏基金會在2024年發布的報告凸顯了這項公共衛生挑戰的嚴峻性，報告顯示，美國有超過1億人患有過敏性疾病。

市場促進因素

免疫療法和生物製藥的日益普及是市場成長的主要驅動力，反映出治療策略正從緩解症狀轉向緩解疾病。臨床醫生經常開立口服和經皮免疫療法等先進療法，這些療法已被證明能有效幫助患者對有害過敏原脫敏。例如，美國過敏、氣喘和免疫學會 (ACAAI) 在 2025 年 11 月的年會上宣布，使用 Viaskin 花生貼片治療的嬰兒中，超過 70% 的人在三年後對特定花生蛋白水平產生了耐受性。這種臨床療效正在推動商業性成功，ALK-Abello 公司於 2025 年 11 月發布的「2025 年第三季展望更新」印證了這一點。該報告將全年銷售成長預期（以該地貨幣計算）上調至 13-15%，因為使用免疫療法產品的患者數量不斷增加。

同時，診斷調查方法的技術進步提高了過敏原檢測的速度和準確性，加速了產業成長。諸如成分分解診斷 (CRD) 和分子診斷等創新技術能夠精確識別特定的過敏原蛋白，最大限度地減少傳統皮膚點刺試驗中常見的交叉反應問題。這種發展趨勢推動了對個人化管理和精準醫療的需求，使醫療保健提供者能夠識別更詳細的過敏原資訊。例如，賽默飛世爾科技公司 2025 年 4 月發布的 2024 會計年度年度報告顯示，其專業診斷業務創造了 45.1 億美元的收入，這體現了該領域重要的經濟意義，也印證了其在全球範圍內對先進診斷工具的強勁投資。

市場挑戰

特定免疫療法方案和先進診斷試劑盒的高成本是全球過敏診斷和治療市場的主要限制因素。儘管精準醫療在臨床上至關重要，但長期減敏療法和分子診斷檢測的高昂費用阻礙了市場滲透，尤其是在價格敏感型經濟體中。因此，醫療服務提供者和患者往往依賴抗組織胺藥物等傳統對症治療，而非尋求根治性療法。這種經濟阻力減少了潛在治療患者的數量，阻礙了對新療法的需求成長，並妨礙了市場充分利用全球日益成長的過敏患者群體。

由於報銷體係不足以抵銷現代過敏症治療的成本，經濟障礙進一步加劇。當保險公司限制或拒絕承保特定診斷和生物製藥時，由此產生的自付費用對許多患者來說難以承受。根據歐洲過敏與臨床免疫學會估計，到2024年，過敏性疾病的直接醫療費用預計在每位患者每年1823歐元至6656歐元之間。如此高昂的人均費用表明，經濟可及性仍然是一個重大瓶頸，直接限制了產生收入，並阻礙了先進治療方案的廣泛應用。

市場趨勢

穿戴式生物感測器的出現，使得消費者能夠在臨床環境之外識別飲食和環境因素，從而改變預防性醫療保健方式，實現即時過敏原檢測。這些攜帶式設備超越了對產品標籤的依賴，利用電化學感測和先進的分子印跡聚合物技術來檢測空氣和食物中的微量過敏原，讓商業性即時安心。 FoodBev Media 2024 年 8 月發布的報告《Amulet 完成 A 輪融資 580 萬美元，推出攜帶式食物過敏原感測器》強調了這項創新技術的商業潛力。報告指出，Amulet 已籌集 580 萬美元，用於擴展其技術，以便隨時隨地檢測麩質和花生等常見過敏原。

此外，基於微生物組的治療方法的進步標誌著治療策略正從傳統的脫敏和對症治療轉向治療導致過敏性超敏反應的根本原因——腸道菌群異常（菌群失調）。這一趨勢強調了具有恢復腸道微生物多樣性、調節免疫反應和預防嬰幼兒「過敏進程」潛力的生物製藥產品（LBPs）。例如，BioSpace在2024年3月發表的一篇報導《Siolta Therapeutics完成C輪資金籌措，籌集1200萬美元用於臨床開發》中報道，該公司已獲得1200萬美元資金，用於推進其旗艦候選藥物STMC-103H的研發。 STMC-103H是一種預先設定的聯合療法，旨在預防新生兒食物過敏和異位性皮膚炎等過敏性疾病的發生。

The Global Allergy Diagnostics and Therapeutics Market is projected to expand from USD 36.33 Billion in 2025 to USD 57.62 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.99%. This sector encompasses medical devices, assay kits, and pharmaceutical interventions designed to identify and manage hypersensitivity reactions to specific allergens. Market growth is primarily fueled by the increasing global prevalence of allergic conditions, such as allergic rhinitis and food allergies, which require distinct clinical management strategies. Additionally, rising urbanization and escalating pollution levels act as key drivers by intensifying exposure to environmental triggers, thereby widening the patient demographic in need of medical attention.

Market Overview
Forecast Period	2027-2031
Market Size 2025	USD 36.33 Billion
Market Size 2031	USD 57.62 Billion
CAGR 2026-2031	7.99%
Fastest Growing Segment	Diagnostics
Largest Market	North America

Despite these positive indicators, the market encounters significant obstacles due to the high costs associated with specific immunotherapy regimens and advanced diagnostic panels, which limit patient access in cost-sensitive developing nations. This financial hurdle is frequently exacerbated by insufficient reimbursement frameworks that slow the broad adoption of innovative treatments. Highlighting the magnitude of this public health challenge, the Asthma and Allergy Foundation of America reported in 2024 that allergic conditions impacted over 100 million individuals in the United States.

Market Driver

The increasing adoption of immunotherapy and biologics serves as a major catalyst for market growth, marking a shift from symptomatic relief to disease-modifying strategies. Clinicians are frequently prescribing advanced treatments, such as oral and epicutaneous immunotherapy, which have proven highly effective in desensitizing patients to dangerous allergens. For example, the American College of Allergy, Asthma & Immunology revealed at its Annual Meeting in November 2025 that over 70% of toddlers treated with the Viaskin Peanut Patch achieved tolerance to specific peanut protein levels after three years. This clinical efficacy is driving commercial success, as evidenced by ALK-Abello's November 2025 'Q3 2025 Outlook Update', which raised full-year revenue growth projections to 13-15% in local currencies due to higher patient volumes for immunotherapy products.

Concurrently, technological advancements in diagnostic methodologies are accelerating sector growth by improving the speed and accuracy of allergen detection. Innovations such as component-resolved diagnostics (CRD) and molecular diagnostics enable the precise identification of specific allergic proteins, thereby minimizing cross-reactivity issues common with traditional skin-prick tests. This evolution facilitates the demand for personalized management and precision medicine, allowing providers to identify sensitivities with granular detail. Demonstrating the economic significance of this segment, Thermo Fisher Scientific's '2024 Annual Report' from April 2025 noted that its Specialty Diagnostics business achieved $4.51 billion in revenue, underscoring the strong global investment in advanced diagnostic tools.

Market Challenge

The high costs associated with specific immunotherapy regimens and advanced diagnostic panels present a major restraint on the Global Allergy Diagnostics and Therapeutics Market. Although precision medicine is clinically necessary, the substantial financial requirements for long-term desensitization therapies and molecular diagnostic assays hinder market penetration, especially in price-sensitive economies. Consequently, healthcare providers and patients often resort to conventional symptomatic treatments, such as antihistamines, rather than pursuing curative interventions. This economic friction reduces the addressable patient population and retards the volume growth of novel therapeutics, thereby preventing the market from fully leveraging the rising global prevalence of allergies.

This financial obstacle is further compounded by inadequate reimbursement structures that frequently fail to offset the expenses of modern allergy management. When insurance providers restrict or deny coverage for component-resolved diagnostics or biologics, the resulting out-of-pocket costs become unmanageable for many patients. According to the European Academy of Allergy and Clinical Immunology, direct healthcare costs for allergic diseases in 2024 were estimated between €1,823 and €6,656 per patient annually. Such high per-capita expenses demonstrate why financial accessibility remains a critical bottleneck that directly limits revenue generation and obstructs the widespread adoption of advanced care solutions.

Market Trends

The emergence of wearable biosensors for real-time allergen detection is transforming preventative management by enabling consumers to identify dietary and environmental triggers outside clinical environments. Moving beyond reliance on product labeling, these portable devices employ electrochemical sensing or advanced molecular imprinted polymers to detect trace allergens in air and food, providing immediate assurance. The commercial potential of this innovation is highlighted by FoodBev Media's August 2024 report, 'Amulet secures $5.8m in Series A round to launch portable food allergen sensors', which notes that Amulet raised $5.8 million to scale technology allowing individuals to test for common allergens like gluten and peanuts on the go.

Additionally, the progression of microbiome-based therapeutic approaches signifies a shift toward treating the underlying dysbiosis responsible for allergic hypersensitivity, differing from traditional desensitization or symptomatic relief. This trend emphasizes live biotherapeutic products (LBPs) aimed at restoring gut microbial diversity to modulate immune responses and potentially halt the "atopic march" in early life. Illustrating significant investment in this area, BioSpace reported in March 2024, in the article 'Siolta Therapeutics Raises $12 Million in Series C Financing for Clinical Development', that the company secured $12 million to advance its lead candidate, STMC-103H, a defined-consortia biotherapeutic developed to prevent the onset of allergic diseases like food allergies and atopic dermatitis in newborns.

Key Market Players

Thermo Fisher Scientific, Inc.
R-Biopharm AG
DASIT Group SPA
AGILUS DIAGNOSTICS LTD.
AESKU.GROUP GmbH
bioMerieux SA
Siemens Healthineers AG
STALLERGENES GREER International AG
HYCOR Biomedical, LLC
Minaris Medical America, Inc.

Report Scope

In this report, the Global Allergy Diagnostics and Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Diagnostics and Therapeutics Market, By Type

Diagnostics
Therapeutics

Allergy Diagnostics and Therapeutics Market, By Allergen Type

Food
Inhaled
Drug
Other Allergens

Allergy Diagnostics and Therapeutics Market, By Test Type

vivo Test
vitro Test

Allergy Diagnostics and Therapeutics Market, By Region

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Diagnostics and Therapeutics Market.

Available Customizations:

Global Allergy Diagnostics and Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Allergy Diagnostics and Therapeutics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Diagnostics, Therapeutics)
- 5.2.2. By Allergen Type (Food, Inhaled, Drug, Other Allergens)
- 5.2.3. By Test Type (vivo Test, vitro Test)
- 5.2.4. By Region
- 5.2.5. By Company (2025)
5.3. Market Map

6. North America Allergy Diagnostics and Therapeutics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By Allergen Type
- 6.2.3. By Test Type
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Allergy Diagnostics and Therapeutics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By Allergen Type
    - 6.3.1.2.3. By Test Type
- 6.3.2. Canada Allergy Diagnostics and Therapeutics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By Allergen Type
    - 6.3.2.2.3. By Test Type
- 6.3.3. Mexico Allergy Diagnostics and Therapeutics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By Allergen Type
    - 6.3.3.2.3. By Test Type

7. Europe Allergy Diagnostics and Therapeutics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By Allergen Type
- 7.2.3. By Test Type
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Allergy Diagnostics and Therapeutics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By Allergen Type
    - 7.3.1.2.3. By Test Type
- 7.3.2. France Allergy Diagnostics and Therapeutics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By Allergen Type
    - 7.3.2.2.3. By Test Type
- 7.3.3. United Kingdom Allergy Diagnostics and Therapeutics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By Allergen Type
    - 7.3.3.2.3. By Test Type
- 7.3.4. Italy Allergy Diagnostics and Therapeutics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By Allergen Type
    - 7.3.4.2.3. By Test Type
- 7.3.5. Spain Allergy Diagnostics and Therapeutics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By Allergen Type
    - 7.3.5.2.3. By Test Type

8. Asia Pacific Allergy Diagnostics and Therapeutics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By Allergen Type
- 8.2.3. By Test Type
- 8.2.4. By Country
8.3. Asia Pacific: Country Analysis
- 8.3.1. China Allergy Diagnostics and Therapeutics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By Allergen Type
    - 8.3.1.2.3. By Test Type
- 8.3.2. India Allergy Diagnostics and Therapeutics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By Allergen Type
    - 8.3.2.2.3. By Test Type
- 8.3.3. Japan Allergy Diagnostics and Therapeutics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By Allergen Type
    - 8.3.3.2.3. By Test Type
- 8.3.4. South Korea Allergy Diagnostics and Therapeutics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By Allergen Type
    - 8.3.4.2.3. By Test Type
- 8.3.5. Australia Allergy Diagnostics and Therapeutics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By Allergen Type
    - 8.3.5.2.3. By Test Type

9. Middle East & Africa Allergy Diagnostics and Therapeutics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By Allergen Type
- 9.2.3. By Test Type
- 9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
- 9.3.1. Saudi Arabia Allergy Diagnostics and Therapeutics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By Allergen Type
    - 9.3.1.2.3. By Test Type
- 9.3.2. UAE Allergy Diagnostics and Therapeutics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By Allergen Type
    - 9.3.2.2.3. By Test Type
- 9.3.3. South Africa Allergy Diagnostics and Therapeutics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By Allergen Type
    - 9.3.3.2.3. By Test Type

10. South America Allergy Diagnostics and Therapeutics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By Allergen Type
- 10.2.3. By Test Type
- 10.2.4. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil Allergy Diagnostics and Therapeutics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By Allergen Type
    - 10.3.1.2.3. By Test Type
- 10.3.2. Colombia Allergy Diagnostics and Therapeutics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By Allergen Type
    - 10.3.2.2.3. By Test Type
- 10.3.3. Argentina Allergy Diagnostics and Therapeutics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By Allergen Type
    - 10.3.3.2.3. By Test Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Global Allergy Diagnostics and Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Thermo Fisher Scientific, Inc.
- 15.1.1. Business Overview
- 15.1.2. Products & Services
- 15.1.3. Recent Developments
- 15.1.4. Key Personnel
- 15.1.5. SWOT Analysis
15.2. R-Biopharm AG
15.3. DASIT Group SPA
15.4. AGILUS DIAGNOSTICS LTD.
15.5. AESKU.GROUP GmbH
15.6. bioMerieux SA
15.7. Siemens Healthineers AG
15.8. STALLERGENES GREER International AG
15.9. HYCOR Biomedical, LLC
15.10. Minaris Medical America, Inc.